Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. (PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults With Moderate to Severe Hidradenitis Suppurativa,” aims to show that this oral drug can reduce symptoms where antibiotics have failed.
The trial tests ritlecitinib, an oral small-molecule drug taken once a day, against a placebo pill. The goal is to see if ritlecitinib can safely ease pain, reduce flare-ups, and improve daily life for people with hidradenitis suppurativa.
This is an interventional trial where participants are randomly assigned to ritlecitinib or placebo, similar to a coin flip. The study is triple blind, so patients, doctors, and study staff do not know who receives the active drug, and the main aim is to test ritlecitinib as a treatment.
The study treatment lasts 16 weeks with a loading dose for 8 weeks and maintenance dosing for another 8 weeks, and total participation is about 24 weeks. The trial is listed as recruiting, with the most recent update on April 28, 2026, which signals that the design and timelines remain active and relevant for investors tracking milestones.
For Pfizer, a positive readout could extend its immunology and inflammation franchise into a niche but growing dermatology segment and support longer-term revenue diversification beyond vaccines and oncology. The update that the study is recruiting and recently refreshed may lift sentiment slightly, especially given rising interest in immune-mediated skin treatments where players like AbbVie, UCB, and emerging biotech firms are also investing.
The ritlecitinib HS program could add optionality to Pfizer’s pipeline, but investors should treat it as a medium-term catalyst given Phase 2 risk and likely years to potential launch. The trial remains ongoing and updated, with further details available on the ClinicalTrials.gov portal under NCT07228390.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.